In 2019, Czech Republic’s leading pharmaceutical company PRO.MED.CS Praha a.s. celebrated its 30th anniversary. Today, this manufacturer supplies products to more than 25 countries, primarily, to the Russian Federation, Central and Eastern Europe, and Central Asia. 

Its portfolio includes pharmaceuticals for the digestive, cardio-vascular, and musculo-skeletal systems. The output of solid dosage forms (tables, coated tablets, and capsules) exceeds 2 million units per day. PRO.MED.CS has its own R&D centres to develop advanced pharmaceuticals on its own. 

The company’s philosophy is to supply the market with tested, effective, and safe pharmaceuticals at a reasonable price. 

Its drugs are manufactured at two modern pharmaceutical production facilities – at the company’s own factory in Prague and at a contractor’s site in the Moscow Region. Both facilities are fitted out with hi-tech equipment meeting the highest international standards. This is attested to by GMP and ISO certificates. It is worth noting that PRO.MED.CS Praha a.s. was among the first foreign pharmaceutical companies to obtain the Russian GMP certificate in addition to the European one.  

PRO.MED.CS has a vast experience in the EAEU markets, which is the reason why it chose to support the panel discussion entitled “Innovations in the Regulatory Framework for the Circulation of Pharmaceuticals in the Eurasian Economic Union” at the 6th All-Russia GMP Conference 2021. The activity will be divided into two parts. The first will be devoted to the topical issues of integration under the EAEU common market of pharmaceuticals. 

The list of contributors includes representatives of the Ministry of Industry and Trade of the Russian Federation, FBI State Institute of Drugs and Good Practices of the Ministry of Industry and Trade of the Russian Federation, Ministry of Health of the Russian Federation, regulatory authorities of the Eurasian Economic Union member states, and Eurasian Economic Commission. 

The agenda for the second part of the panel is as follows: technology transfer and production scaling, development of Russian full-cycle production facilities, system of state standard reference samples in Russia, and other topical issues.